Pharmaceuticals

Yuyu Pharma to attend 'CPHI Worldwide 2023'

SEOUL, South Korea, Oct. 18, 2023 /PRNewswire/ -- Yuyu Pharma will be attending CPHI Worldwide inBarcelona, Spain from October 24th to October 26th. Yuyu Pharma to attend ‘CPHI Worldwide 2023’ The Yuyu Business Development team will be able to meet...

2023-10-18 15:00 4520

Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures

* These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients aged 6 to 17 for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus. * The primary efficacy endpoint was...

2023-10-18 14:00 1817

Bridging the Healthcare Gap in Thailand and Beyond with the Belt and Road Initiative

BANGKOK, Oct. 18, 2023 /PRNewswire/ -- "I have a dream that everyone should have the ability to access medical care equally," says Oraphan Wanacharoen (Ice), BGI Genomics Field Application Scientist. "It's very challenging to achieve such a goal inThailand. With the advanced technology of the com...

2023-10-18 08:21 3134

Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion

SAN DIEGO and SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors identified using the PrismCore™ platform. The CAR-T, term...

2023-10-17 23:17 2506

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedica...

2023-10-17 17:00 4729

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...

2023-10-16 07:48 2218

Offering broader access to sustainable and scalable pharma-grade saponin adjuvants

SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants ...

2023-10-13 21:47 3017

GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS

SEOUL, South Korea, Oct. 13, 2023 /PRNewswire/ -- Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly exten...

2023-10-13 09:00 3197

Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

Metabolon's newest panels help academic and commercial researchers reveal complex biological insights about liver fibrosis and kidney dysfunction MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of lif...

2023-10-12 19:57 1689

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

HANGZHOU and SHAOXING, China, Oct. 11, 2023  /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...

2023-10-11 08:10 3176

SAFETYscan47: A Valuable Component in Revolutionizing Chemical Risk Assessments for Global Health and Safety

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk a...

2023-10-10 23:10 2558

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

-- STX-721 is characterized by high selectivity and a potentially best-in-class profile -- -- Scorpion's second program to enter clinical development this year -- -- One of two EGFR programs being developed with Pierre Fabre Laboratories --  BOSTON and CASTRES, France, Oct. 10, 2023 /PRNewswire/...

2023-10-10 18:00 1854

AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL

Expands Portfolio of Cataract Surgery Solutions for Patients in Greater China to New Extended Monofocal Segment AffaMed Therapeutics and SIFI Leadership Celebrate Strong Progress of the AffaMed Technologies Joint-Venture BEIJING, Oct. 10, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a ...

2023-10-10 09:00 3583

Kaneka Files Patent Infringement Lawsuit Against CoCrystal

TOKYO, Oct. 10, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit inthe United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and mon...

2023-10-10 03:47 3567

Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration

ROCKVILLE, Md. and SUZHOU, China, Oct. 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2023-10-09 08:00 6727

Xinhua Silk Road: Xinhua-Hengshan Astragalus Membranaceus Market Index unveiled in China's Shanxi

BEIJING, Oct. 8, 2023 /PRNewswire/ -- The Xinhua-Hengshan Astragalus Membranaceus Market Index was recently unveiled in Hunyuan County, northChina's Shanxi Province. Xinhua-Hengshan Astragalus Membranaceus Market Index unveiled in China’s Sha...

2023-10-08 10:02 6382

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

SHANGHAI, Oct. 5, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") presented new biomarker and subgroup analyses from Nefecon®'s Phase 3 NefIgArd study in both posters and ...

2023-10-05 07:33 3071

Amcor's AmSky™ and AmPrima™ earn Walmart's 'Circular Connector' seal of approval

ZURICH, Oct. 4, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, has been recognized for itsAmSky™  andAmPrima™

2023-10-04 23:55 6312

Large-scale proteomics in population-based studies from UK and Iceland

REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome an...

2023-10-04 23:00 3166

Kensing to Acquire AOM

Acquisition expands Kensing's Natural Vitamin E and phytosterols product offerings. KANKAKEE, Ill., Oct. 4, 2023 /PRNewswire/ -- Kensing, LLC ("Kensing" or the "Company"), a leading manufacturer of Natural Vitamin E, Plant Sterols and high-purity surfactants, and a portfolio company owned by an ...

2023-10-04 21:00 4164
1 ... 74757677787980 ... 186